Gallbladder events in the product documents
All three regulators treat gallbladder disease as a warning rather than a minor reaction. [1][2][3] The Canadian monograph gives two sets of figures: its warning section repeats the US rates for reported adverse events, while its adverse reaction table lists gallstones in 51 of 3,384 people (1.5%) against 10 of 1,941 (0.5%). The document does not explain the difference between the two. [3]
| Document and term | Saxenda® | Placebo | Note |
|---|---|---|---|
| US label 5.3; Canada warning, gallstones [1][3] | 2.2% | 0.8% | Most needed gallbladder removal |
| US label 5.3; Canada warning, cholecystitis [1][3] | 0.8% | 0.4% | Inflamed gallbladder |
| Canadian monograph, Table 3, cholelithiasis [3] | 51 of 3,384 (1.5%) | 10 of 1,941 (0.5%) | Adverse reaction table |
| EU SmPC, Table 4 [2] | Gallstones common; cholecystitis uncommon | — | May lead to hospital stay and surgery |
| US label, section 6.2 [1] | Cholestasis, hepatitis, raised bilirubin | — | Post-approval reports, no rate |
What the numbers mean in practice
Roughly one or two more adults in every hundred developed gallstones on Saxenda® than on placebo during trials lasting up to 56 weeks. [1] The figures are small, but the events were not: the US label says most people with gallstones or cholecystitis on Saxenda® needed a cholecystectomy, the operation to remove the gallbladder. [1]
The weight-loss question matters. Substantial or rapid weight loss is a known cause of gallstones, and the labels accept that. They add that it does not explain everything: the higher rate on liraglutide remained after allowing for how much weight people lost, or in the EU wording, weight loss only partially explained it. [1][2] The US counselling section also tells patients that gallbladder disease can happen without substantial or rapid weight loss. [1]
Liver test changes can be a clue. In the trials, a few people on Saxenda® had very high liver enzyme levels, and some of these rises were linked with gallstones. [1]
What studies add
A 2022 systematic review and meta-analysis in JAMA Internal Medicine pooled 76 randomised trials with 103,371 people. GLP-1 medicines were associated with a 37% higher relative risk of gallbladder or bile duct disease overall. The increase was larger in weight-loss trials, at higher doses and with longer use. [4]
A 2025 meta-analysis of 55 placebo-controlled trials put the extra risk of gallstones at about two more cases per 1,000 people, and found the increase more marked in trials of people with overweight or obesity, though that subgroup difference was not statistically significant. [5]
Two Danish trials looked at how liraglutide affects the gallbladder itself. In 52 adults over 12 weeks, liraglutide 3 mg did not change the maximum amount the gallbladder emptied after a fatty liquid meal, but the median time to reach it was 151 minutes against 77 minutes on placebo. [6] A follow-up analysis found changes in three gut hormones that control gallbladder filling and emptying, which the authors suggest may explain slower refilling after meals. [7] These were small physiology studies; they show a plausible route, not proof of how stones form.
Other risk factors for gallstones
- MedlinePlus lists female sex, being over 40, overweight, a family history of gallstones, and Native American or Hispanic descent. [9]
- Diabetes, pregnancy, liver cirrhosis, birth control pills and long-term feeding through a vein also raise the risk. [9]
- Rapid weight loss from a very low-calorie diet or after weight-loss surgery is a recognised cause, independent of any medicine. [9][11]
- Gallstones are common and often silent; many are found by chance on scans and do not need treatment. [9][10]
What the sources say about prevention and care
MedlinePlus states that most gallstones cannot be prevented, but that in people with obesity, avoiding rapid weight loss may help. [9] The NIH digestive diseases institute suggests a healthy eating plan with fibre-rich foods, whole grains and healthy fats such as olive and fish oils, less sugar and refined carbohydrate, and regular activity, and advises talking to a health professional before changing your eating plan. [11]
The US label asks prescribers to arrange gallbladder tests and follow-up if gallstones are suspected, and asks patients to contact their provider if gallbladder disease is suspected. [1] The EU leaflet goes further for severe pain: stop Saxenda® and contact a doctor immediately if you have severe upper belly pain, usually worst on the right under the ribs, which may reach the back or right shoulder. [2]
Whether Saxenda® continues after a gallbladder problem is a decision for your prescriber; the labels do not give a rule for restarting after gallbladder surgery.
Saxenda® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
The signs and contact information below come from this article’s sourced guidance.
Emergency
- Severe pain in the upper belly, worst on the right under the ribs, possibly reaching the back or right shoulder
Contact: Stop Saxenda® and contact a doctor immediately
- Belly pain lasting several hours with fever or chills, yellow skin or eyes, tea-coloured urine or pale stools
Contact: A doctor right away
- Severe pain spreading to the back with vomiting, which can mean gallstone pancreatitis
Contact: Stop Saxenda® and seek care straight away